AUG 14, 2018 11:30 PM PDT

Single Antiplatelet Drug Reduces Risk of Blood Clots

WRITTEN BY: Nouran Amin

Image Retrieved From Unsplash, www.unsplash.com

According to the current treatment protocol, patients that undergo minimally invasive aortic heart valve replacements will likely receive two antiplatelet drugs that reduce the likelihood of developing dangerous blood clots. Now, a new meta-analysis study by Loyola Medicine has found that administering just one antiplatelet drug is sufficient enough to reduce the risk of life-threatening bleeding in comparison to two of these drugs. The study was published in the July issue of the American Journal of Cardiology and led by Verghese Mathew, MD, a renowned interventional cardiologist and chair of Loyola's division of cardiology.

The aortic valve is responsible for regulating blood flow from the hearts main pumping chamber, the left ventricle, to the body’s largest artery, the aorta. Aortic stenosis is caused by the narrowing of the aortic valve, which can cause chest pain and fatigue to many affected individuals, and severe symptoms can lead to heart failure and death. To replace a diseased aortic valve usually required an open heart surgery. But in 2011, a minimally invasive technique was developed to implant an artificial valve with a catheter. The technique is known as transcatheter aortic valve replacement (TAVR) where the catheter is inserted into an artery in the groin and is led up to the heat where the valve is placed.

Watch Video Below To Understand TAVR:

 

TAVR is commercially available in the United States. After administering TAVR, patients usually take two antiplatelets known as ‘dual-antiplatelet therapy’ to reduce the risk of developing blood clots. Commonly used antiplatelet drugs are aspirin and clopidogrel (Plavix). However, the treatments vary depending on the cardiologist assigned. Some providers prescribe their patients just one antiplatelet called the ‘mono-antiplatelet therapy’ usually when the patients have an increased concern of bleeding from the dual-antiplatelet therapy. However, in the study, Dr. Mathew and team analyzed the results of eight studies that compared mono-antiplatelet therapy to the use of dual-antiplatelet therapy. The studies examined 2,439 patients in total and in four of these studies, patients were deployed the Sapien aortic valve and in two studies, they received the CoreValve device. Finally, in two of these studies, both valves were administered. During 30 days, patients given two antiplatelet agents were 2.06 times more likely to die, 2.04 times more likely to develop life-threatening bleeding and 2.15 times more likely to undergo major vascular complications. "These data suggest a safety concern with dual-antiplatelet therapy and underscore the need for a large randomized trial to definitely address this question," Dr. Mathew and colleagues wrote.

Source: Loyola University Health System

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 18, 2018
Drug Discovery
OCT 18, 2018
Potential Drug Target for Tactile Allodynia
According to research published in the journal Science Translational Medicine in collaboration with a study led by the National Institutes of Health, a new...
DEC 05, 2018
Cancer
DEC 05, 2018
Zika virus as a weapon against brain cancer
Glioblastoma is the most aggressive type of Brain Cancer with an average survival rate of less than two years with treatment. So what if there could be a cure for this type of cancer....
DEC 18, 2018
Drug Discovery
DEC 18, 2018
Increasing Misuse of Prescription Drugs
According to a study published in Psychiatric Services in Advance, misuse of prescription drugs accounts for more than 17 percent of overall use. In the st...
DEC 19, 2018
Drug Discovery
DEC 19, 2018
Promising Drug for ALS?
ALS, standing for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease affecting the nerve cel...
DEC 26, 2018
Drug Discovery
DEC 26, 2018
Compound Shrinks Tumors of Sarcoma Cells
According to a multi-disciplinary study carried out by the University of Illinois, a compound was found to effectively shrink tumors in animal models by ta...
JAN 14, 2019
Drug Discovery
JAN 14, 2019
Vitamin D Proved Non-Beneficial for Individuals Aged 70 and Over
According to a study in the American Journal of Clinical Nutrition, researchers at Newcastle University have confirmed that older individuals, over the age...
Loading Comments...